Objective-To examine the long-term benefits and safety of aerobic training in patients with chronic heart failure.
Over the past 15 years several published reports have described the effects of a physical training programme in patients with compensated chronic heart failure due to systolic ventricular dysfunction.l "The reported benefits include improved exercise tolerance, an increased peak oxygen intake, and at least partial relief from the symptoms of breathlessness, undue fatigue, sleep disturbance, and muscle weakness. None of the exercise programmes have encountered any adverse occurrences. Nonetheless, consideration of such patients for referral to a cardiac rehabilitation exercise programme has not become a customary option, as it has in the case of patients recovering from myocardial infarction, aorto-coronary artery bypass surgery, percutaneous transluminal coronary angiography, and cardiac transplantation. There are a number of reasons for the reluctance to prescribe exercise. The ominous nature of the condition favours a cautious approach. From the Framingham Study5 we know that 50% of patients with chronic heart failure die within five years of the initial diagnosis. Two exercise training reports have also suggested that sub-sets of heart failure patients (those with low ejection fractions and ST segment depression on exercise testing6 and those with extensive anterior infarcts7) might not benefit from exercise training and might even be affected adversely. On the other hand, Giannuzzi and associates noted that although patients with poor left ventricular function after anterior myocardial infarction were prone to further global and regional dilatation, long-term exercise conferred a significant improvement in physical work capacity and did not have an additional negative effect. 8 There remains the need for a large controlled prospective trial to assess the value of medically prescribed and supervised exercise training in this group of patients. In the meantime, however, some physicians find the existing evidence favouring exercise sufficiently persuasive to warrant referring their appropriately treated chronic heart failure patients for exercise training in the out-patient rehabilitation setting. The objectives of this non-randomised study, which included a control group, were (i) to examine the safety and efficacy of progressive aerobic training in chronic chronic heart failure when treatment was sustained for a year, a much longer period of training than has been examined by other investigators; (ii) to explore associations between gains of cardiorespiratory function and improvements in perceived quality of life; and (iii) to plot the time course of such changes.
Patients and methods STUDY DESIGN
Eligible patients completed an initial quality of life and cardiorespiratory function assessment, and this was repeated two weeks later. The first test served to familiarise patients with procedures, and the second provided baseline data. Patients then entered a programme of individually prescribed, supervised aerobic training. Quality of life and cardiorespiratory function measurements were repeated after four, eight, 12, and 16 weeks of exercise training, and further evaluations were performed after 26 and 52 weeks.
Given the length of the study, and the poor prognosis in such patients, it was not considered feasible to maintain a comparable control group for 52 weeks. However, a sample of nine subjects were observed for a total of 12 weeks before entering the exercise programme. This enabled us to determine the stability of the measures that were used in the absence of an exercise training programme.
PATIENTS
All patients were recruited in accordance with Sunnybrook Health Science Centre guidelines for written informed consent. The experimental group comprised 21 patients (17 men and 4 women, aged 62 (6) years); the control subgroup sample comprised 8 men and 1 woman, aged 64-8 (5 6) years. Selection criteria included: age 21 to 70 years, New York Heart Association (NYHA) functional class II or III, disability related to symptoms of chronic heart failure, ability to perform a progressive symptom-limited treadmill test for at least 3 minutes (modified Naughton protocol, 3 METs or 10-5 ml/[kg.min]), and clinical stability for a period of at least one month. Maintenance doses of digoxin, frusemide, and angiotensinconverting-enzyme inhibitors, as well as con- (1-5).
CHF, chronic heart failure; NYHA, New York Heart Association; LVEF, resting left ventricular ejection fraction.
comitant treatment with antihypertensive drugs, nitrates, and calcium antagonists were permitted if dosages had remained unchanged for at least one month before the start of the study.
Reasons for exclusion from the study included a scintigraphic resting left ventricular ejection fraction greater than 40%, /B blocker therapy, the presence of symptomatic angina sufficiently severe to limit even low level training, myocardial infarction or cardiac surgery within the previous three months, obstructive cardiomyopathy, reversible causes of chronic heart failure, pacemaker dependency, and any coexisting condition which would preclude the proposed aerobic training or seemed likely to limit survival to less than one year.
The aetiology of the chronic failure was ischaemic in 15 cases, valvar in 3, idiopathic in 2, and ethanol-related in 1 ( Measurements were also made of the respiratory rate, respiratory minute volume, ventilatory (anaerobic) threshold, and peak oxygen intake, using a SensorMedics Horizon Metabolic Cart. Details of the ventilatory threshold determination have been described previously. '4 In brief, the primary criterion of ventilatory threshold was the oxygen intake at which the ventilatory equivalent for oxygen began to increase, corroboration being sought from an increase in respiratory minute volume, a carbon dioxide output that was disproportionate to the increase of power output, and a rapid increase of respiratory gas exchange ratio. Data were expressed as the oxygen intake at the ventilatory threshold (millilitres per kilogram per minute, standard temperature and pressure, dry (STPD)) and the percentage of peak oxygen intake corresponding to these criteria.
Because of their low initial fitness levels, a significant proportion of patients with chronic chronic heart failure did not meet our normal criterion of maximal oxygen intake (an oxygen consumption plateau, defined as an increment in oxygen consumption of less than 150 millilitres per minute from the penultimate to the final stage of the cycle ergometer test). Subsidiary criteria of peak effort were a heart rate close to the anticipated age-related maximum (220 minus the age in years), a respiratory gas exchange ratio greater than 1.1 010 15 16 and a rating of perceived exertion of 19 or 20 units on the Borg scale.
Resting ventricular ejection fraction was measured by radionuclide ventriculography at entry to the programme and after 52 weeks. Other measurements included height and body mass; a skinfold estimate of percentage body fat based on triceps, subscapular, and suprailiac skinfolds, as measured by Harpenden Calipers'7; and the maximal grip force of the dominant hand as measured by Stoelting handgrip dynamometer.
CHRONIC HEART FAILURE QUESTIONNAIRE The Chronic Heart Failure Questionnaire'8 is a disease-specific health-related quality of life questionnaire which assesses the patient's dyspnoea during day-to-day activities (5 questions), fatigue (4 questions), emotional function (7 questions), and coping with the illness ("mastery", 4 questions). Responses to each item are scored on a 7-point scale. The The standard gamble has the advantage of fulfilling the fundamental axioms of utility theory.'920 Patients are offered two alternatives: the status quo, with the prospect of living with the existing disability for life, or taking a gamble on treatment for which the outcome is uncertain. The patient is told that the proposed treatment will lead to perfect health with a probability of p, but a probability of 1 -p that it will cause certain death. The value of p is varied, using a coloured wheel, until the patient perceives no difference between the alternatives of the treatment and the status quo. The probability value chosen by an individual at any given assessment summarises their perceived quality of life on a single scale that ranges from 0 (death) to 1 0 (full health).
EXERCISE TRAINING REGIMEN
The individualised aerobic training prescription was based on progressive walking. It followed the general practice of the Toronto Rehabilitation Centre." The initial intensity of training was based on the results of the laboratory exercise test, as indicated by the ventilatory threshold, 50-60% of peak oxygen intake, and a perception of 13-14 on the Borg scale of perceived exertion. During the first 16 weeks patients attended the Toronto Rehabilitation Centre five times per week, and carried out the walk accompanied by a rehabilitation therapist. Initially, the total weekly distance averaged 10 km (range 6-16 km) at an average pace of 13 minutes per km. Over the first 16 weeks the distance was increased progressively to 21 km (16-33 km), and the average pace was boosted to 115 minutes per km. Thereafter, the training programme continued for one year, with visits to the exercise classes at the rehabilitation centre once weekly for a further 20 weeks, and then once monthly for the final 16 weeks. Throughout the period of reduced visits, the patients carried out their prescribed walk away from the centre, for a total of five exercise sessions weekly. Compliance was excellent; on average, patients attended 95% of the supervised exercise sessions during the first 16 weeks of training, 86% of the sessions during the subsequent 36 weeks, and completed 78% of the required home sessions.
STATISTICAL ANALYSES
Descriptive data are presented as mean (SE) of the mean. Changes in cardiorespiratory function and quality of life measured over the period of the study were analysed using an ANOVA for repeated measures. Where statistical significance was established, individual differences from initial readings were tested using Fisher's protected least significance difference test, with P set at < 0 05. All graphs indicate the significance of differences from initial values: a = P<005, b = P<0 01, c = There were six patients who did not complete 52 weeks, and paired comparisons have been based on those who were still continuing to exercise at a given time point. (1-3) (99% CI 0 3 to 11L3, P < 0 001) by the end of the programme. The New York Heart Association class improved from class II to class I in one patient, from III to II in nine, remained at class II in one, and remained at class III in four. Fifteen of the 21 patients initially enrolled in the exercise programme completed all 52 weeks of the trial successfully. Three patients were withdrawn because of an apparent worsening of chronic failure, but in no instance did this appear related to the exercise programme. Patient 6 began experiencing extreme fatigue after 4 weeks of training-he was subsequently diagnosed as having developed hypothyroidism. Patient 12 developed atrial fibrillation with increasing chronic heart failure, and in consequence he was withdrawn from the study at 4 weeks. Patient 15 was removed from the study at 8 weeks because of worsening chronic heart failure. Patient 18 had a cardiac arrest while shopping for groceries at week 16 of the trial, and he was withdrawn from the study for this reason. He subsequently received an implantable defibrillator. Two other patients withdrew from the study for non-cardiac reasons; patient 13 became non-compliant after 16 weeks and refused to return for subsequent testing, and patient 2 was unable to walk at 52 weeks because of a painful spur in the right foot. In the remaining 15 Weeks training Weeks training Figure 4 Changes in additional physiological variables over 52 weeks of aerobic training. Values (delta (SE)) in patients with chronic heartfailure for: peak heart rate, peak systolic blood pressure, peak respiratory gas exchange ratio, and body mass index. Sample size 17 subjects 0-16 weeks, 15 subjects at 26 and 52 weeks. (a = P < 0 05, b = P<001,c = P<0001).
(mean (SD), 93-4 (5-3)%). A qualitative measure of compliance was provided by the distance walked per week. (FIG 1) Significant improvements in the speed of the six-minute test walk continued throughout the trial. An initial pace of 81 (13) metres/min had risen (ANOVA, P < 0 0035) to 95 (13) metres/min at 16 weeks, an improvement of some 18% (LSD P < 0-0001); thereafter, values were sustained at a plateau (98&8 ± 12-8 metres/min at 52 weeks). More than half of this response was already apparent at the 4-week test (pace = 88 (14) metres/min; least significant difference, P < 0 009).
SIX-MINUTE WALK
CARDIORESPIRATORY FUNCTION (TABLE 2, FIG 2) Gains of cardiorespiratory function, as indicated by peak oxygen intake (ANOVA, P < 0 0003), resting heart rate (ANOVA, P < 0007), ventilatory (anaerobic) threshold (ANOVA, P < 0028), and peak power output (ANOVA, P < 0O0001), tended to develop a little more slowly than the improvement in walking pace, with a suggestion of a plateau between the fourth and the eighth weeks of treatment, a peaking of gains at 16 weeks, and little deterioration of function thereafter. The peak oxygen intake increased progressively, with a peak gain at 16 weeks; the 4 week gain was 38% of this response. The resting heart rate decreased progressively, the largest decrease being seen at 26 weeks. The 4 week change in heart rate was 52% of this response. The ventilatory threshold showed its largest training response after 52 weeks of training; the 4 week response was only 35% of this. The peak power output showed a peak gain at 16 weeks of training; the 4 week response amounted to 51% of this change.
FACTORS ASSOCIATED WITH CARDIOVASCULAR

RESPONSE (TABLE 2, FIGS 3 AND 4)
The gain in peak exercise performance was associated with an increase in minute ventilation (ANOVA, P < 0021), the peak increase being seen at 52 weeks of training. There was also a small trend to an increase of oxygen pulse (ANOVA, P < 0 066); this response was maximal at 16 weeks of training, and at 4 weeks (NS) was only 33% of this. Lean body mass showed only minor and erratic changes over the period of observation. Handgrip force also failed to show significant changes. The maximum rate-pressure product tended to increase beyond the eighth week of training (ANOVA, P < 0 19), the peak gain at 26 weeks amounting to about 8-7%. This reflected a progressive and statistically significant augmentation of peak heart rate (ANOVA, P < 0037), the peak gain being seen after 52 weeks of training. The peak systolic blood pressure also tended to increase over the study (ANOVA, P < 0085), the maximum change being seen at 26 weeks of training. Changes in peak respiratory gas exchange ratio were erratic, but the body mass index tended to a small decline over the course of the experiment (ANOVA, P < 0-091); the largest decrease was seen at 26 weeks.
CHANGES IN THE QUALITY OF LIFE (FIGS 5 AND 6)
The chronic heart failure questionnaire showed a trend to improvement on all four perceptions of the quality of life. A decrease in fatigue (ANOVA, P < 0O001) and trends to decreased dyspnoea (ANOVA, P < 0 1 improved emotional function (ANO P < 0-132), and increased mastery (ANO P < 0O149) showed a general parallel to phz logical gains, with improvement over the four weeks of training, but continuing prog over at least 26 weeks of observation. standard gamble showed a 14% improven (ANOVA, P < 0O0035) from an initial ass ment of 76 (18) (LSD, P < 0O0001), with ( of this change occurring over the first weeks of training (LSD, P < 0O0085); va peaked over the first 16 weeks of the; gramme, but the improvement was lar sustained throughout the 52 weeks of observation.
Discussion SUSTAINED BENEFIT
Previous authors have demonstrated that patients with chronic chronic heart failure show short-term benefits in response to a programme of progressive aerobic exercise. However, this is the first investigation to provide detailed data showing that functional gains can be maintained over a year of continuing exercise and observation. Sustained improvements in physiological measures such as peak oxygen intake, peak power output, ventilatory threshold, and resting heart rate were associated with major improvements in the quality of life and functional ability as measured by habitual walking speed. Demonstration that the functional gains persist is important, because an exercise programme cannot be administered in a double blind manner. Over the initial 12 weeks of control observations all measures, with the possible exception of emotional function, were unchanged, despite the fact that the patients were receiving close medical attention and observation throughout this period. It could be argued that the exercise programme itself could have induced an early placebo response. However, such a response would have waned as involvement in the programme continued, whereas the present results showed wellsustained physiological and psychological improvements.
MECHANISM OF BENEFIT
The hypotheses that have been invoked previously to explain the improved function of trained heart failure patients have included a correction of lean tissue loss associated with prolonged immobilisation,2" enhancement of oxidative metabolism in the leg muscles, 2224 and a decrease in respiratory minute volume at any given carbon dioxide output.25
The present study sheds some additional light upon potential mechanisms of benefit. Given the training-related increases in peak heart rate, peak ventilation, peak systolic pressure, and peak respiratory gas exchange ratio, it is arguable that the extra medical attention increased the patients' confidence, allowing them to exercise to a higher level of peak effort with each successive test. However, the absence of change during 12 weeks of control observations that included participation in four maximal laboratory stress tests speaks against such a hypothesis, and the equally large gains in oxygen transport at the ventilatory threshold provide strong evidence that the programme did more than induce a simple increase in peak effort on the part of the patients.
There was a small trend to a decrease in body mass-1-1% at 16 weeks and 2-2% in 52 weeks. Other factors being equal, this would have increased the relative peak oxygen intake (expressed in ml/[kg.min], but not the absolute peak oxygen intake. Thus the (a = P < 0-05, b = P < 001, c = P < 0.001).
response cannot be attributed simply to a reduction of body mass over the period of exercise training. If the patients showed an excessive ventila- tory response to exercise, this might reduce exercise capacity by diverting the available oxygen intake from the leg to the respiratory muscles.26 Such a problem would not in itself alter the individual's peak oxygen intake (because the measurement does not identify where the oxygen is being used), but it would restrict the patient's peak power output. Over the course of the training period, the ventilatory equivalent for carbon dioxide showed a non-significant decrease at a fixed submaximal work rate (fig 7) . The peak ventilatory equivalent for both carbon dioxide and oxygen also decreased slightly (table 2) . However, the observed improvement, about 5% in both values, was smaller than the gain in either the absolute peak oxygen intake (15-0% at 16 weeks, l 1-4% at 52 weeks) or the peak power output (11-3% at 16 weeks, 11L2% at 52 weeks). Moreover, there was not much of a discrepancy between the gains in peak power output and peak oxygen intake. Thus although the training programme tended to decrease the ventilatory equivalent for carbon dioxide and oxygen, probably by improving the aerobic enzyme activity of the muscles,22-24 27 it seems unlikely that this change made a major contribution to the observed increase of aerobic performance. This leaves an improvement of cardiovascular function as the main probable source of benefit. Because of training-induced alterations of autonomic balance27 and autonomic sensitivity of the heart, the cardiac stroke volume may have been increased and/or a larger fraction of the cardiac output may have been directed to the working tissues. This suggestion is supported by the improvement in resting left ventricular ejection fraction. At the onset of training, the peak oxygen pulse was also low (8-9 (2 9) ml/beat); a trend to a 103% increase was seen after 16 weeks of training, but a lesser response of 5-1% was seen at 52 weeks. Assuming that there was a parallel 103% gain of stroke volume at 16 weeks, this would explain most of the observed improvement in aerobic performance. Support for a shift of autonomic regulation and/or an increase of stroke volume is provided by the decrease of resting heart rate over the training period.
FUNCTIONAL CONSEQUENCES
The observed gains in aerobic power (fig 8) and performance of the 6-minute walk test (fig 9) correlated significantly with each of the four measures of subjective response (fatigue, dyspnoea, emotional function, and mastery). However, the gains in submaximal performance (the chosen speed of walking) showed a closer correlation with improvement in symptoms than did gains in aerobic power (respective significance of linear regression coefficients, P = 00002 to 00036 and P = 0026 to 0039). The explanation for this probably lies in the more subjective nature of the self-selected walking speed.
The response to exercise was substantially greater in those with a low initial quality of life, significantly so for dyspnoea (r = 057; P = Relation between training-induced gain in distance walked over six minutes and symptom scores forfatigue, dyspnoea, emotionalfunction, and mastery.
0-017), mastery (r = 0-65; P = 0 005), and the standard gamble (r = 0-82; P = 0O0001 
